M. Campone

1.1k total citations
21 papers, 217 citations indexed

About

M. Campone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M. Campone has authored 21 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in M. Campone's work include Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Bone health and treatments (3 papers). M. Campone is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Bone health and treatments (3 papers). M. Campone collaborates with scholars based in France, Switzerland and United States. M. Campone's co-authors include Douglas Bootle, Éric Raymond, N. Shand, Vincent Lévy, Emmanuelle Bourbouloux, Fabien Calvo, Catherine Dutreix, Jaafar Bennouna, Tanya Taran and David Cameron and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

M. Campone

18 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Campone France	8	128	86	79	44	32	21	217
Siddharth Kunte United States	6	126 1.0×	52 0.6×	65 0.8×	15 0.3×	34 1.1×	13	227
Jon S. Dubois United States	3	209 1.6×	212 2.5×	65 0.8×	91 2.1×	61 1.9×	4	285
A. Stopeck United States	9	242 1.9×	80 0.9×	68 0.9×	90 2.0×	10 0.3×	20	295
Marice Alcantara United States	9	111 0.9×	44 0.5×	95 1.2×	46 1.0×	11 0.3×	12	218
Glenn Buene Norway	10	92 0.7×	25 0.3×	181 2.3×	35 0.8×	19 0.6×	14	299
Sheida Hayati United States	4	94 0.7×	188 2.2×	141 1.8×	98 2.2×	21 0.7×	13	298
Ruth Wills United States	7	156 1.2×	42 0.5×	119 1.5×	89 2.0×	6 0.2×	7	296
Dafna Kaufman United States	8	89 0.7×	59 0.7×	130 1.6×	39 0.9×	32 1.0×	10	257
Michela Palleschi Italy	9	189 1.5×	133 1.5×	75 0.9×	75 1.7×	41 1.3×	46	281
G. Lieberman United States	5	148 1.2×	85 1.0×	99 1.3×	40 0.9×	22 0.7×	9	231

Countries citing papers authored by M. Campone

Since Specialization

Citations

This map shows the geographic impact of M. Campone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Campone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Campone more than expected).

Fields of papers citing papers by M. Campone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Campone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Campone. The network helps show where M. Campone may publish in the future.

Co-authorship network of co-authors of M. Campone

This figure shows the co-authorship network connecting the top 25 collaborators of M. Campone. A scholar is included among the top collaborators of M. Campone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Campone. M. Campone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yardley, Denise A., Yoon Sim Yap, Hamdy A. Azim, et al.. (2022). 205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Annals of Oncology. 33. S629–S629. 4 indexed citations

Hortobágyi, G. N., Salomon M. Stemmer, H.A. Burris, et al.. (2021). LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Annals of Oncology. 32. S1290–S1291. 41 indexed citations

Campone, M., Michelino De Laurentiis, Claudio Zamagni, et al.. (2019). Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial. Annals of Oncology. 30. v115–v115. 3 indexed citations

Bouvard, Béatrice, P Soulié, Patrick Saulnier, et al.. (2018). Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. European Journal of Cancer. 101. 87–94. 8 indexed citations

Sonke, Gabe S., M. Campone, Frans Erdkamp, et al.. (2017). Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2. European Journal of Cancer. 72. S1–S2. 6 indexed citations

André, Fabrice, Patrick Neven, Antonino Musolino, et al.. (2013). Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study. Cancer Research. 73(24_Supplement). OT2–6. 2 indexed citations

Campone, M., Christelle Lévy, Mónica Arnedos, et al.. (2013). Abstract S6-07: Genomic characterisation of metastatic samples from breast cancer patients using next generation sequencing. Cancer Research. 73(24_Supplement). S6–7. 2 indexed citations

Nguyen, Frédérique, Catherine Ibisch, Delphine Loussouarn, et al.. (2012). Immunophenotypic Classification of Feline Mammary Carcinomas. Journal of Comparative Pathology. 146(1). 79–79.

Pierga, Jean‐Yves, David Hajage, Thomas Bachelot, et al.. (2012). 353 Assessment of Circulating Tumor Cells and Serum Markers for Progression-free Survival Prediction in Metastatic Breast Cancer: a Prospective Observational Study. European Journal of Cancer. 48. S146–S146. 3 indexed citations

10.

Melichar, Bohuslav, E. Casado, Jaafar Bennouna, et al.. (2011). Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. British Journal of Cancer. 105(11). 1646–1653. 16 indexed citations

11.

Nguyen, Frédérique, Jérôme Abadie, Delphine Loussouarn, et al.. (2011). PD08-10: High Frequency of Triple Negative Mammary Carcinomas in the Dog as Model of Human Breast Cancer.. Cancer Research. 71(24_Supplement). PD08–10.

12.

Frenel, Jean‐Sébastien, Christophe Leux, Delphine Loussouarn, et al.. (2011). Predictive value of IDH1 mutation assessed by immunohistochemistry and DNA sequencing in WHO grade 3 oligodendrogliomas.. Journal of Clinical Oncology. 29(15_suppl). 2002–2002. 2 indexed citations

13.

Censi, Andrea De, Zheng Sun, B. Thürlimann, et al.. (2011). Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.. Journal of Clinical Oncology. 29(15_suppl). 516–516.

14.

Frenel, Jean‐Sébastien, Mari Botti, Delphine Loussouarn, & M. Campone. (2009). Facteurs pronostiques et prédictifs de réponse des gliomes cérébraux de l’adulte. Bulletin du Cancer. 96(4). 357–367. 9 indexed citations

15.

Campone, M., Vincent Lévy, Emmanuelle Bourbouloux, et al.. (2009). Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. British Journal of Cancer. 100(2). 315–321. 74 indexed citations

16.

Poznak, Catherine Van, R.A. Hannon, Glen Clack, et al.. (2009). Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).. Cancer Research. 69(2_Supplement). 1137–1137. 14 indexed citations

17.

Bonneterre, Jacques, M. Campone, Maria Błasińska-Morawiec, et al.. (2006). Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemotherapy and Pharmacology. 60(3). 365–373. 7 indexed citations

18.

Bennouna, Jaafar, J. Medioni, Frédéric Rolland, et al.. (2005). Phase I clinical trial of BromoHydrin PyroPhosphate, BrHPP (Phosphostim), a Vγ9Vδ2 T lymphocytes agonist in combination with low dose Interleukin-2 in patients with solid tumors. Journal of Clinical Oncology. 23(16_suppl). 2536–2536. 13 indexed citations

19.

Campone, M., Jeany M. Rademaker-Lakhai, Jaafar Bennouna, et al.. (2004). 606 Phase I and pharmacological study of AP5346, an HPMA copolymer-linked DACH platinum therapeutic, in patients with solid progressive tumors. European Journal of Cancer Supplements. 2(8). 183–183. 2 indexed citations

20.

Campone, M., Vincent Lévy, Valérie Delecroix, et al.. (2004). 359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors. European Journal of Cancer Supplements. 2(8). 108–108. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact